breast cancer

[Journal of Experimental & Clinical Cancer Research] Scientists summarize current clinical trials, which assessed the safety and efficacy of breast cancer stem cells-related therapies.

[Journal of Translational Medicine] Scientists explored the function of circular RNA nucleolar and coiled-body phosphoprotein 1 (circNOLC1) in cancer stem cells of breast cancer and the inhibitory impact of propofol on circNOLC1.

[Cancer Biology & Medicine] The authors describe the biological effects of estrogen, progesterone, and their metaboliteson the proliferation of breast cancer cells, based on relevant research and clinical trials, to improve our understanding of the biological functions of estrogen and progestogen and safety of menopausal hormone therapy.

[British Journal of Cancer] Genome-wide association studies coupled with large-scale replication and fine-scale mapping studies have identified more than 150 genomic regions that are associated with breast cancer risk. Investigators review efforts to translate these findings into a greater understanding of disease mechanism.

[Daiichi Sankyo Company, Limited] Daiichi Sankyo Company, Limited announced that the first patient was dosed in the global TROPION-Breast01 phase III trial evaluating the efficacy and safety of datopotamab deruxtecan in patients with hormone receptor positive, human epidermal growth factor 2 receptor (HER2) negative inoperable or metastatic breast cancer.

[CytoDyn, Inc.] CytoDyn, Inc. announced that Health Canada authorized the emergency use of leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, for the treatment of a patient with metastatic triple-negative breast cancer.